Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.
Anant RamaswamyPrabhat BhargavaSujay SrinivasAkhil KapoorBal Krishna MishraAnuj GuptaSarika MandavkarSadhana KannanDeepali ChauguleRajshree PatilManali ParulekarChaitali NashikkarSuman Kumar AnkathiRajiv Kumar KaushalDeepali NaughaneAnuprita DaddiNeha MerNitin ShettyVikas OstwalPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The combination of bevacizumab and erlotinib as switch maintenance improves progression-free survival with an acceptable safety profile compared with active surveillance in patients with advanced BTCs in this phase II study. The trial moves on to the phase III component to evaluate improvement in overall survival.
Keyphrases
- phase iii
- open label
- free survival
- phase ii study
- phase ii
- advanced non small cell lung cancer
- placebo controlled
- double blind
- clinical trial
- epidermal growth factor receptor
- metastatic colorectal cancer
- cancer therapy
- study protocol
- photodynamic therapy
- locally advanced
- randomized controlled trial
- combination therapy
- tyrosine kinase